Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 GLC determination of medroxyprogesterone acetate in plasma.

× No keyword cloud information.

9 in total

Review 1. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors: P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal: Clin Pharmacokinet Date: 1992-05 Impact factor: 6.447

Review 2. Long acting contraceptives. Present status.

Authors: G Benagiano; F M Primiero
Journal: Drugs Date: 1983-06 Impact factor: 9.546

3. Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.

Authors: C M Camaggi; E Strocchi; M Giovannini; B Angelelli; B Costanti; E Zebini; P Ferrari; F Pannuti
Journal: Cancer Chemother Pharmacol Date: 1983 Impact factor: 3.333

4. [High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles].

Authors: H E Wander; C Blossey; J Köbberling; G A Nagel
Journal: Klin Wochenschr Date: 1983-06-01

5. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.

Authors: C M Camaggi; E Strocchi; N Canova; B Costanti; F Pannuti
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

6. Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.

Authors: C M Camaggi; E Strocchi; B Costanti; P Beghelli; P Ferrari; F Pannuti
Journal: Cancer Chemother Pharmacol Date: 1985 Impact factor: 3.333

7. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability.

Authors: J Frick; G Bartsch; G Jakse
Journal: Urol Res Date: 1977

8. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer.

Authors: H C Blossey; H H Bartsch; D Kanne; J Koebberling; G A Nagel
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

Review 9. Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors: Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal: Pharmacol Ther Date: 2020-12-13 Impact factor: 13.400

9 in total